These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 18711791)

  • 1. Multiple biomarkers and cardiovascular risk.
    Austin MJ; Heneghan MA
    N Engl J Med; 2008 Aug; 359(7):760-1; author reply 761. PubMed ID: 18711791
    [No Abstract]   [Full Text] [Related]  

  • 2. Multiple biomarker panels for cardiovascular risk assessment.
    de Lemos JA; Lloyd-Jones DM
    N Engl J Med; 2008 May; 358(20):2172-4. PubMed ID: 18480211
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes.
    Zethelius B; Berglund L; Sundström J; Ingelsson E; Basu S; Larsson A; Venge P; Arnlöv J
    N Engl J Med; 2008 May; 358(20):2107-16. PubMed ID: 18480203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should we focus on novel risk markers and screening tests to better predict and prevent cardiovascular disease? Or are we putting the cart before the horse?
    Wong ND
    Prev Cardiol; 2010; 13(4):149-51. PubMed ID: 20860636
    [No Abstract]   [Full Text] [Related]  

  • 5. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease.
    Nozaki T; Sugiyama S; Koga H; Sugamura K; Ohba K; Matsuzawa Y; Sumida H; Matsui K; Jinnouchi H; Ogawa H
    J Am Coll Cardiol; 2009 Aug; 54(7):601-8. PubMed ID: 19660689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative NT-proBNP and CRP predict perioperative major cardiovascular events in non-cardiac surgery.
    Nadir MA; Struthers AD
    Heart; 2010 Aug; 96(15):1254; author reply 1254. PubMed ID: 20639243
    [No Abstract]   [Full Text] [Related]  

  • 7. N-terminal-pro-B-type natriuretic peptide: universal marker of cardiovascular risk?
    Richards AM; Frampton CM
    Circulation; 2005 Jul; 112(1):9-11. PubMed ID: 15998694
    [No Abstract]   [Full Text] [Related]  

  • 8. [Value of biological markers in cardiovascular disease].
    Couderc R; Lefevre G; Fiessinger JN
    Bull Acad Natl Med; 2012 Jan; 196(1):217-22. PubMed ID: 23259345
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of cardiac biomarkers in end-stage renal disease.
    Wang AY; Lai KN
    J Am Soc Nephrol; 2008 Sep; 19(9):1643-52. PubMed ID: 18322158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should we focus on novel risk markers and screening tests to better predict and prevent cardiovascular disease? Point.
    Enriquez JR; de Lemos JA
    Prev Cardiol; 2010; 13(4):152-9. PubMed ID: 20860637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker sensitivity and specificity require pre-test probability of disease diagnosis to be collated: additional points on the interpretation of pro-B-type natriuretic peptide triage of dyspnea in the Copenhagen Heart Study.
    MacFadyen RJ; Chuen MJ
    J Am Coll Cardiol; 2008 Apr; 51(13):1322-3; author reply 1323. PubMed ID: 18371568
    [No Abstract]   [Full Text] [Related]  

  • 12. Relation of adiponectin and high-sensitivity C-reactive protein to pulse-wave velocity and N-terminal pro-B-type natriuretic peptide in the general population.
    Sung SH; Chuang SY; Sheu WH; Lee WJ; Chou P; Chen CH
    Am J Cardiol; 2009 May; 103(10):1411-6. PubMed ID: 19427438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminoterminal natriuretic peptides and cardiovascular risk in an Italian male adult cohort.
    Barbato A; Sciarretta S; Marchitti S; Iacone R; Di Castro S; Stanzione R; Cotugno M; Ippolito R; Palmieri L; Calvieri C; Battistoni A; Volpe M; Strazzullo P; Rubattu S;
    Int J Cardiol; 2011 Oct; 152(2):245-6. PubMed ID: 21862156
    [No Abstract]   [Full Text] [Related]  

  • 14. Incremental value of high-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide for the prediction of postoperative cardiac events in noncardiac vascular surgery patients.
    Goei D; Hoeks SE; Boersma E; Winkel TA; Dunkelgrun M; Flu WJ; Schouten O; Bax JJ; Poldermans D
    Coron Artery Dis; 2009 May; 20(3):219-24. PubMed ID: 19322079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B-type natriuretic peptide for risk stratification in community-acquired pneumonia.
    Mueller C; Laule-Kilian K; Scholer A; Perruchoud AP
    J Intern Med; 2005 Oct; 258(4):391-3. PubMed ID: 16164581
    [No Abstract]   [Full Text] [Related]  

  • 16. Understanding cardiovascular biomarkers.
    Hieronymus L; Wortzman-Show G
    Diabetes Self Manag; 2013; 30(3):16, 18-20. PubMed ID: 23951629
    [No Abstract]   [Full Text] [Related]  

  • 17. Natriuretic peptides in heart failure: their role in daily practice.
    Loboz-Grudzień K; Jaroch J
    Cardiol J; 2009; 16(1):1-3. PubMed ID: 19130409
    [No Abstract]   [Full Text] [Related]  

  • 18. The latest and greatest new biomarkers: which ones should we measure for risk prediction in our practice?
    de Lemos JA
    Arch Intern Med; 2006 Dec 11-25; 166(22):2428-30. PubMed ID: 17159006
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical relevance of a raised plasma N-terminal pro-brain natriuretic peptide level in a population-based cohort of nonagenarians.
    Vaes B; de Ruijter W; Degryse J; Westendorp RG; Gussekloo J
    J Am Geriatr Soc; 2009 May; 57(5):823-9. PubMed ID: 19470010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amino-terminal brain natriuretic peptide is related to the presence of diabetic polyneuropathy independently of cardiovascular disease.
    Jurado J; Ybarra J; Ferrandiz M; Comerma L; Pou JM
    Diabetes Care; 2007 Aug; 30(8):e86. PubMed ID: 17855271
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.